Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Topcon Healthcare Acquires RetInSight to Advance AI-Powered Imaging in Eye Care
Topcon Healthcare announced May 2 that it had acquired privately held retinal AI analysis company RetInSight, of Austria. No financial details were disclosed. The companies forged a partnership in ...
Q1-2025 Ophthalmic Revenue Roundup for Amgen, Hoya, Apellis, Tarsus, STAAR, RxSight, and Ocular Therapeutix
Amgen, of Thousand Oaks, California, reported May 1 that its Q1-2025 revenue from Tepezza was $381 million, a 10 percent decrease from $424 million in Q1-2024. The total consisted of $365 million...
Elanco Sells US Royalty and Milestone Rights for Xdemvy to Blackstone for $295 Million
Elanco, of Greenfield, Indiana, announced May 5 that it had sold certain future US tiered royalties and commercial milestone payments associated with Tarsus’ Xdemvy (lotilaner ophthalmic solution 0...
Okyo Pharma Accelerates Development of Urcosimod in Neuropathic Corneal Pain
London’s Okyo Pharma announced April 30 that it would accelerate development of urcosimod, formerly OK-101, in neuropathic corneal pain, following early closure of its Phase II trial. The trial was...
US FDA Grants Marketing Clearance for OcuSciences’ OcuMet Beacon Retinal Imager
OcuSciences, of Ann Arbor, Michigan, announced May 1 that the US FDA had granted marketing clearance for its flagship device, the OcuMet Beacon retinal imager. The 510(k) clearance describes the Oc...
RetinAI and FVS Gain CE Marking for LuxIA DR Screening Algorithm
Switzerland’s RetinAI and Spain’s Fundación Ver Salud (FVS) announced April 30 that LuxIA, their co-developed artificial intelligence algorithm for diabetic retinopathy screening, had received CE m...
Aldeyra Achieves Primary Endpoint in Phase III Dry Eye Chamber Trial of Reproxalap, Plans NDA Resubmission
Aldeyra Therapeutics reported May 5 that topical reproxalap achieved the primary endpoint of statistically significant improvement in ocular discomfort vs. vehicle in a Phase III dry eye chamber tr...
US FDA Grants RMAT Status to Opus’ LCA5 Gene Therapy Candidate
Opus Genetics announced May 6 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to OPGx-LCA5, its investigational gene therapy for the treatment of Leber congeni...
US FDA Grants RMAT Status to 4DMT’s Gene Therapy Candidate in DME
4D Molecular Therapeutics announced May 1 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to 4D-150, an intravitreal gene therapy candidate for diabetic macula...
US FDA Extends Luminopia Amblyopia Treatment Clearance to Children Ages 8 to 12
Luminopia announced April 22 that the US FDA had cleared its amblyopia (lazy eye) treatment for patients ages 8 to 12, extending the age range of its existing label. The Luminopia system was grante...
Q1-2025 Ophthalmic Revenue Roundup for Roche, Regeneron, AbbVie, Glaukos, Lumibird, and Biogen
Swiss company Roche reported April 24 that Vabysmo sales in Q1-2025 were CHF 1 billion ($1.1 billion, calculated March 31, 2025), up 18 percent in constant currency from CHF 847 million in Q1-2024....
New Laws in Montana, West Virginia Expand ODs’ Scope to Include Laser
Montana and West Virginia became the 13th and 14th US states, respectively, to pass laws expanding optometrists’ scope of practice to include in-office laser procedures. West Virginia’s measure spe...
Past News Stories
Formosa Licenses Clobetasol Propionate Drops to Chile’s Saval for Latin America
Taiwan-based Formosa Pharmaceuticals announced April 25 that it had agreed to license to Chile’s Laboratorios Saval exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical...
NanoDrops Names Daria Lemann-Blumenthal as CEO
Israel’s NanoDrops announced April 22 that it had appointed Belkin Vision co-founder Daria Lemann-Blumenthal as its new chief executive officer. NanoDrops, founded in 2020, employs a laser-etched p...
Allotex Ramps Up Commercialization of Presbyopia Implant, Appoints Michael Mrochen, PhD, as CEO
Allotex announced April 23 the acceleration of commercialization of its human collagen-based corneal implant for presbyopia—along with the appointment of company co-founder Michael Mrochen, PhD, as...
CSI Dry Eye Software Appoints Ken Barbet as CEO
CSI Dry Eye Software, an artificial intelligence-based platform to aid dry eye disease diagnosis and management, announced April 23 that it had appointed Ken Barbet as chief executive officer. CSI ...
Aurion Biotech Appoints Edward J. Holland, MD, as Chief Medical Officer
Aurion Biotech announced April 23 that it had appointed Edward J. Holland, MD, as chief medical officer. Aurion’s lead asset is AURN001, being developed for corneal edema secondary to corneal endot...
Design Therapeutics Appoints Chris M. Storgard, MD, as Chief Medical Officer
Design Therapeutics announced April 17 that it had appointed Chris M. Storgard, MD, as chief medical officer (CMO). The Carlsbad, California, company is developing DT-168, a small molecule targetin...
Bausch + Lomb Ends Recall of enVista IOLs After Tracking Source of Contamination
Bausch + Lomb announced April 24 that it was ending its voluntary recall of enVista intraocular lenses (IOLs) after it tracked the source of contamination to a raw material used in certain lots tha...
GA Patients in Eyestem Phase I Cell Therapy Trial Show Significant Vision Improvement
India’s Eyestem Research reported April 15 that patients with geographic atrophy (GA) in a Phase I trial of its Eyecyte-RPE cell therapy saw significant vision improvement. Eyecyte-RPE is a cryopre...
Four Eylea Biosimilars Get Q-Codes for Billing Payers in the US
The Centers for Medicare and Medicaid Services (CMS) issued product-specific Q-codes for four Eylea biosimilars during Q4-2024 and Q1-2025. Q-codes are billing codes for reimbursement that are simi...
Alcon Rolls Out Unity VCS and CS Systems at ASCRS Meeting
Alcon announced April 25 the launch of its dual-function Unity Vitreoretinal Cataract System (VCS) and stand-alone Unity Cataract System (CS) in four markets, including the US. The announcement cam...
Veo Launches Plexitome to Treat Recurrent Corneal Erosion, Corneal Abrasions
Veo Ophthalmics, of Chester, Ohio, announced April 14 that it had launched its Plexitome surgical instrument for the treatment of recurrent corneal erosion and large corneal abrasions. The FDA-regi...
US FDA Rejects Regeneron’s sBLA for Eylea HD Dosing Interval Beyond 16 Weeks
Regeneron announced April 18 that the US FDA had issued a complete response letter rejecting the company’s supplemental biologics license application (sBLA) to add extended dosing intervals up to e...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.